{"id":"lurasidone-20-40-60-80-mg-flexibly-dosed","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Akathisia"},{"rate":"8-12","effect":"Somnolence"},{"rate":"5-10","effect":"Parkinsonism"},{"rate":"5-8","effect":"Nausea"},{"rate":"5-7","effect":"Headache"},{"rate":"3-5","effect":"Tremor"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lurasidone acts as an antagonist at dopamine D2 receptors and serotonin 5-HT7 receptors, with high binding affinity and selectivity for these targets. This dual mechanism helps regulate neurotransmitter activity implicated in psychotic and mood disorders. The drug has minimal affinity for histamine and muscarinic receptors, which may contribute to a favorable side-effect profile compared to older antipsychotics.","oneSentence":"Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:31.163Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder depression"}]},"trialDetails":[{"nctId":"NCT01986101","phase":"PHASE3","title":"A Phase III Study of SM-13496 in Patients With Bipolar I Depression.","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2014-02-19","conditions":"Bipolar Depression","enrollment":525},{"nctId":"NCT01914393","phase":"PHASE3","title":"Pediatric Open-Label Extension Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2013-09-30","conditions":"Schizophrenia, Autism, Bipolar Depression","enrollment":702},{"nctId":"NCT01485640","phase":"PHASE3","title":"Lurasidone Extended Use Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-06","conditions":"Schizophrenia, Bipolar Disorder","enrollment":162}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Latuda"],"phase":"phase_3","status":"active","brandName":"Lurasidone 20, 40, 60, 80 mg, flexibly dosed","genericName":"Lurasidone 20, 40, 60, 80 mg, flexibly dosed","companyName":"Sumitomo Pharma America, Inc.","companyId":"sumitomo-pharma-america-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lurasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT7 receptors in the brain. Used for Schizophrenia, Bipolar I disorder depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}